Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897159 | 0.93 | ROCK2 (0.49) | MAOBROCK2TP53SRCROCK1 | |
| SCHEMBL4888626 | 0.90 | MAOB (0.50) | MAOBROCK2TP53SRCROCK1 | |
| SCHEMBL4896946 | 0.90 | SRC (0.57) | MAOBROCK2SRCROCK1 | |
| SCHEMBL4886692 | 0.89 | SRC (0.51) | MAOBROCK2TP53SRCROCK1 | |
| SCHEMBL4899110 | 0.84 | HDAC1 (0.44) | MAOBROCK2SRC | |
| SCHEMBL4897239 | 0.81 | SRC (0.55) | ROCK2SRCEGFRROCK1MAPT | |
| SCHEMBL4899116 | 0.81 | SRC (0.48) | MAOBROCK2SRCEGFRROCK1 | |
| SCHEMBL4890357 | 0.79 | SRC (0.47) | ROCK2SRCROCK1 | |
| SCHEMBL4899454 | 0.77 | SRC (0.56) | MAOBROCK2SRCEGFRROCK1 | |
| SCHEMBL254400 | 0.77 | ROCK2 (0.62) | MAOBROCK2TP53SRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | claimed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | claimed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | SGK1, SGK2, SGK3 | MAOB 4611/4885ROCK2 1337/4885TP53 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.